Consistently, N6L dramatically decreases both the active form of ErbB1 receptor (EGFR) (Figure 5B) and ERK1/2 (Figure 5C), known to be implicated in proliferation, migration and invasion of glioma cells [16–17]. Here, EGFR is linked to central nervous system cancer.